ESMO 2025: ITM's Dr Andrew Cavey on next-gen RPTs

Oncology

At this year’s European Society for Medical Oncology (ESMO) Annual Meeting, pharmaphorum web editor Nicole Raleigh spoke with radiopharmaceutical biotech Isotope Technologies Munich SE (ITM) CEO Dr Andrew Cavey.

The radiopharmaceutical industry is experiencing a surge in innovation and application, with a focus on precision medicine and the treatment of hard-to-treat cancers. And Cavey discusses ITM’s work in this field, specifically in the treatment of GEP-NETs, as well as how RPTs may be on the cusp of becoming a first-line oncology treatment, and other insights from and around data shared at the Congress.

Explore this and other conversations and news from ESMO 2025 here.

Nicole Raleigh

19 October, 2025

ESMO 2025

/themes/custom/pharmaphorum_theme/library/img/article-label-image/ondemand.png

Sales & Marketing

Physicians walking and using tablet devices

How to meet your physicians where they are online

A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.